On Tuesday, May 26, 2026, researchers tracked two developments in GLP-1 drug testing. One involves an experimental pill from Eli Lilly, and the other involves a new drug being tested in patients with both high blood pressure and obesity. Neither development changes the medications available to patients today, but each shows how GLP-1 treatments are being tested for new uses and new forms. If you take a GLP-1 medication now, these studies are worth watching rather than acting on.
A Phase 1 study of LY3502970, an experimental GLP-1 pill from Eli Lilly, has been completed in healthy participants. This kind of study is an early step in drug development. Researchers give the drug to healthy volunteers, not patients, to see how the body absorbs and processes it and to check for basic safety concerns. The results have been posted, but this stage does not tell us whether the pill works for weight loss or blood sugar control. It also has no effect on any GLP-1 medication currently available to patients, since LY3502970 is still years away from potential approval, if it reaches that point at all.
IBI362 has moved into a different stage of testing altogether. A Phase 3 trial is now recruiting patients who have both high blood pressure and obesity, to see how the drug performs in this specific group. Phase 3 trials are larger and later stage than Phase 1, and they are often the last step before a drug applies for approval. Testing IBI362 in people with high blood pressure suggests that researchers see potential value for patients managing both conditions at once, though a trial opening for recruitment does not guarantee the drug will succeed or reach approval.
If you are managing high blood pressure and obesity, this trial may be worth discussing with your doctor if you are interested in participating, though enrollment does not mean the drug is proven to work. If you are simply following GLP-1 research, both developments are worth noting as signs of where testing is headed. Neither study changes what is available to patients right now, so there is no need to adjust any current treatment based on this news.
Key details
A Phase 1 study of Eli Lilly's future GLP-1 pill LY3502970 in healthy participants is…
IBI362, a new GLP-1 drug, has entered Phase 3 recruitment for patients who have both…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-05-26